Supplementary Material for: Visual Outcomes Based on Early Response to Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema

<b><i>Objective:</i></b> To examine the relationship between early response to anti-vascular endothelial growth factor (VEGF) treatment and visual prognosis. <b><i>Methods:</i></b> We retrospectively separated 20 patients with persistent diabetic macular edema (DME) into two responder status groups based on the reduction of central macular thickness (CMT) from baseline to month 3: a delayed responder group (DRG) (≤25% CMT reduction, <i>n</i> = 11) and an immediate responder group (IRG) (>25% CMT reduction, <i>n</i> = 14). We also separated the patients into two responder status groups based on the logarithm of the minimum angle of resolution (logMAR) best-corrected visual acuity (BCVA): a visual nonimprovement group (VNIG) (≥0 logMAR BCVA improvement, <i>n</i> = 11) and a vi sual improvement group (VIG) (<0 logMAR BCVA improvement, <i>n</i> = 14). Finally, we assessed the correlations between logMAR BCVA changes from baseline to month 3 (ΔBCVA<sub>M3</sub>) and those from baseline to month 12 (ΔBCVA<sub>M12</sub>). <b><i>Results:</i></b> At month 12, BCVA was significantly more improved in the VIG than the VNIG (<i>p</i> < 0.005), but was not significantly different between the DRG and the IRG (<i>p</i> = 0.75). The Pearson correlation coefficient showed a significant relationship between ΔBCVA<sub>M3</sub> and ΔBCVA<sub>M12</sub> (<i>r</i> = 0.60, <i>p</i> < 0.005). <b><i>Conclusions:</i></b> BCVA showed significantly greater improvement in the VIG than in the VNIG. ΔBCVA<sub>M3</sub> may predict the visual outcome at month 12 in DME patients treated with anti-VEGF drugs.